An AI-based decision support solution for diagnosis and prognostication of prostate cancer
About CADESS™
CADESS™ will help determine who can live with prostate cancer and who requires surgery to survive.
CADESS.AI was founded in 2016 with the mission to improve patient outcome and reduce healthcare costs for prostate cancer by delivering innovative digital pathology decision support solutions.
We offer CADESS™, an AI-based decision support system for hospital and commercial pathology laboratories involved in diagnosis and prognostication of prostate cancer.
CADESS™ is based on state-of-the-art deep learning and imaging analysis technology and helps determine who can live with prostate cancer and who requires aggressive treatment to survive.
- CADESS™ offers improved diagnostic accuracy resulting in reduced patient suffering and lower treatment costs.
- Fast and accurate identification of malignant glands in tissue images helps pathologists determine the aggressiveness of the cancer.
- CADESS™ was validated at Uppsala University Hospital on the pathology department’s clinical workflow.
- First version offered as cloud-based pay-per-use service solution.
Technology
CADESS™ is a cloud-based decision support system based on mature technology
CADESS™ runs on a cloud GPU-platform infrastructure to enable cost-effective and scalable software as a service. OpenSeaDragon gives an interface similar to that of GoogleMaps, with efficient pan and zoom which pathologists expect from their experience with microscopes. The client devices may use any modern browser.
RESEARCH
CADESS™ is based on ten years of solid research at Uppsala University.
Meet the CADESS™ team
CONTACT
Head office:
CADESS Dag Hammarskjölds väg 34A SE-752 37 Uppsala Sweden |
|
+46 (0) 73 048 20 25 | |
contact@cadess.ai |
North America regional office:
CADESS.AI regional office 21 Oakley Ave Summit, NJ 07901 USA |
|
+1-908-591-1675 | |
contact@cadess.ai |